Literature DB >> 1832057

Synergistic interactions between interleukin-11 and interleukin-4 in support of proliferation of primitive hematopoietic progenitors of mice.

M Musashi1, S C Clark, T Sudo, D L Urdal, M Ogawa.   

Abstract

Interleukin-11 (IL-11) is a newly identified lymphohematopoietic cytokine originally derived from the primate bone marrow stromal cell line, PU-34. Separately, we reported that IL-11 augments IL-3-dependent proliferation of primitive murine hematopoietic progenitors in culture. We have now examined the synergistic interactions between IL-11 and IL-4 in support of colony formation from marrow cells of mice treated 2 days before with 150 mg/kg 5-fluorouracil. Neither recombinant human IL-11 nor murine IL-4 alone was effective in the support of colony formation. When the two factors were combined, there was major enhancement of colony formation, including that of multilineage colony-forming cells. Serial observations (mapping studies) of development of multipotential blast cell colonies indicated that the synergy between IL-11 and IL-4 is due in part to shortening of the dormant period of the stem cells, an effect very similar to that of IL-6 and granulocyte colony-stimulating factor. The combination of IL-11 and IL-4 may be useful in the stimulation of dormant hematopoietic stem cells in vivo.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1832057

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

1.  Negative cross-talk between interleukin-3 and interleukin-11 is mediated by suppressor of cytokine signalling-3 (SOCS-3).

Authors:  F Magrangeas; O Boisteau; S Denis; Y Jacques; S Minvielle
Journal:  Biochem J       Date:  2001-01-15       Impact factor: 3.857

2.  Clonal proliferation of murine lymphohemopoietic progenitors in culture.

Authors:  F Hirayama; J P Shih; A Awgulewitsch; G W Warr; S C Clark; M Ogawa
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-01       Impact factor: 11.205

3.  A multicenter randomized, double-blind, placebo-controlled late-phase II/III study of recombinant human interleukin 11 in acute myelogenous leukemia.

Authors:  Kensuke Usuki; Akio Urabe; Yasuo Ikeda; Yasuo Ohashi; Hideaki Mizoguchi; Fumimaro Takaku
Journal:  Int J Hematol       Date:  2007-01       Impact factor: 2.490

4.  Thrombopoietic potential and serial repopulating ability of murine hematopoietic stem cells constitutively expressing interleukin 11.

Authors:  R G Hawley; T S Hawley; A Z Fong; C Quinto; M Collins; J P Leonard; S J Goldman
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

5.  Negative regulation of early B lymphopoiesis by interleukin 3 and interleukin 1 alpha.

Authors:  F Hirayama; S C Clark; M Ogawa
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-18       Impact factor: 11.205

6.  Interleukin-11: a new cytokine critical for osteoclast development.

Authors:  G Girasole; G Passeri; R L Jilka; S C Manolagas
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

7.  Growth factor requirements for survival in G0 and entry into the cell cycle of primitive human hemopoietic progenitors.

Authors:  A G Leary; H Q Zeng; S C Clark; M Ogawa
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

8.  A herpesvirus saimiri protein required for interleukin-2 independence is associated with membranes of transformed T cells.

Authors:  T Lund; M M Medveczky; P Geck; P G Medveczky
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

9.  Interleukin-11: stimulation in vivo and in vitro by respiratory viruses and induction of airways hyperresponsiveness.

Authors:  O Einarsson; G P Geba; Z Zhu; M Landry; J A Elias
Journal:  J Clin Invest       Date:  1996-02-15       Impact factor: 14.808

10.  Cloning of a murine IL-11 receptor alpha-chain; requirement for gp130 for high affinity binding and signal transduction.

Authors:  D J Hilton; A A Hilton; A Raicevic; S Rakar; M Harrison-Smith; N M Gough; C G Begley; D Metcalf; N A Nicola; T A Willson
Journal:  EMBO J       Date:  1994-10-17       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.